US31572Q8087 - Common Stock
FIBROGEN INC
NASDAQ:FGEN (5/1/2024, 7:00:00 PM)
After market: 1.2 +0.03 (+2.56%)1.17
+0.05 (+4.46%)
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 592 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.
FIBROGEN INC
409 Illinois Street
San Francisco CALIFORNIA 94158
P: 14159781200
CEO: Enrique Conterno
Employees: 592
Website: https://www.fibrogen.com/
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of...
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated,...
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will...
Here you can normally see the latest stock twits on FGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: